2 research outputs found
A novel Tn antigen epitopeârecognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma
Mucin 1 (MUC1) expression is upregulated in multiple types of cancer, including lung cancer. However, the conventional antiâMUC1 antibody is not useful for the differentiation of malignant lung tumors and benign lesions due to its limited specificity. Our previous study screened a novel epitopeâdefined antibody against cancerâassociated sugar chain structures that specifically recognizes the MUC1 Tn antigen (MUC1âTn ED Ab). In the present study, its potential utility as a diagnostic marker and therapeutic tool for lung adenocarcinoma (ADC) was examined. Immunohistochemical analysis of a lung ADC tissue microarray was performed using the MUC1âTn ED Ab (clone SNâ102), and the results were compared with those of another clone and commercially available MUC1 antibodies. The association between positive immunoreactivity of SNâ102 and clinicopathologic factors was analyzed. Furthermore, the association between MUC1âTn expression and epithelialâmesenchymal transition markers and radiological characteristics was analyzed. Moderate or high MUC1âTn expression (MUC1âTnâH) was observed in 138 (78.9%) of the 175 lung ADC cases. MUC1âTnâH was associated with male sex, cigarette smoking, tumor extension, pleural invasion, and higher preoperative serum carcinoembryonic antigen and cytokeratin 19 fragment levels. Tumors with MUC1âTnâH had higher consolidation/tumor ratios according to computed tomography and greater uptakes of 18Fâfluorodeoxyglucose. A total of 46 (26.9%) of the tumors had mesenchymal features, and MUC1âTn positivity was higher in the mesenchymal group than in the epithelial and intermediate groups (P<0.01 and P<0.01, respectively). Patients with tumors exhibiting MUC1âTnâH had significantly shorter 5âyear overall and diseaseâfree survival times (P=0.011 and P<0.001, respectively). Additionally, MUC1âTnâH was identified as an independent prognostic factor in multivariate analysis (P=0.024). MUC1âTn is specific for lung cancer cells and can improve diagnostic capabilities. Additionally, it may be a potential therapeutic target in lung ADC